GEORGE CHOLANKERIL to Liver Cirrhosis
This is a "connection" page, showing publications GEORGE CHOLANKERIL has written about Liver Cirrhosis.
Connection Strength
2.472
-
The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults. J Pediatr Gastroenterol Nutr. 2024 Jul; 79(1):110-118.
Score: 0.541
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
Score: 0.140
-
Cost of Care for Patients With Cirrhosis. Am J Gastroenterol. 2024 03 01; 119(3):497-504.
Score: 0.129
-
Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
Score: 0.123
-
Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2023 02; 43(1):89-99.
Score: 0.122
-
Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol. 2020 04; 11(4):e00165.
Score: 0.102
-
Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. Liver Int. 2019 09; 39(9):1661-1671.
Score: 0.097
-
Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. Hepatology. 2019 03; 69(3):1064-1074.
Score: 0.094
-
Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019 02; 31(2):149-156.
Score: 0.094
-
Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. Hepatol Int. 2019 Mar; 13(2):205-213.
Score: 0.094
-
Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis. Hepatol Int. 2019 Jan; 13(1):84-90.
Score: 0.093
-
Low-Normal Thyroid Function Is Associated With Advanced Fibrosis Among Adults in the United States. Clin Gastroenterol Hepatol. 2019 10; 17(11):2379-2381.
Score: 0.093
-
Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis. Nutrients. 2017 Oct 13; 9(10).
Score: 0.086
-
Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017 Oct; 29(10):1109-1117.
Score: 0.086
-
Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017 Oct; 112(10):1495-1505.
Score: 0.084
-
Association between food insecurity and metabolic dysfunction-associated steatotic liver disease/significant fibrosis measured by fibroscan. Eur J Nutr. 2024 Apr; 63(3):995-1001.
Score: 0.033
-
Exposure to Agent Orange and Hepatocellular Carcinoma Among US Military Personnel. JAMA Netw Open. 2023 12 01; 6(12):e2346380.
Score: 0.033
-
Using noninvasive clinical parameters to predict mortality and morbidity after cardiac interventions in patients with cirrhosis: A systematic review. Saudi J Gastroenterol. 2024 01 01; 30(1):14-22.
Score: 0.033
-
Predictive Algorithm for Hepatic Steatosis Detection Using Elastography Data in the Veterans Affairs Electronic Health Records. Dig Dis Sci. 2023 12; 68(12):4474-4484.
Score: 0.033
-
Chronic liver disease-related mortality during the COVID-19 pandemic. Eur J Intern Med. 2023 12; 118:129-132.
Score: 0.033
-
The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure. J Hepatol. 2023 09; 79(3):717-727.
Score: 0.032
-
Trends in aetiology-based hospitalisation for cirrhosis before and during the COVID-19 pandemic in the United States. Aliment Pharmacol Ther. 2023 07; 58(2):218-228.
Score: 0.032
-
Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States. Dig Liver Dis. 2023 01; 55(1):3-10.
Score: 0.030
-
Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation. Clin Gastroenterol Hepatol. 2023 08; 21(9):2410-2412.e1.
Score: 0.030
-
Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States. Clin Gastroenterol Hepatol. 2022 10; 20(10):2307-2316.e3.
Score: 0.030
-
Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic. Clin Gastroenterol Hepatol. 2021 12; 19(12):2664-2666.e2.
Score: 0.028
-
Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. Clin Gastroenterol Hepatol. 2022 06; 20(6):e1438-e1455.
Score: 0.028
-
Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017-2018. J Gen Intern Med. 2022 01; 37(1):261-263.
Score: 0.027
-
Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018. Clin Gastroenterol Hepatol. 2021 07; 19(7):1499-1501.e2.
Score: 0.026
-
Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Aliment Pharmacol Ther. 2019 09; 50(5):590-598.
Score: 0.024
-
Proton Pump Inhibitors and the Possible Development of Hepatic Encephalopathy in Cirrhotic Patients: True Association or Residual Confounding? Gastroenterology. 2017 06; 152(8):2076.
Score: 0.021
-
Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast. Hepatology. 2017 01; 65(1):393.
Score: 0.020